Tag Archives: regn

LinkedIn, Palo Alto, Regeneron Profit Estimates Rising

It’s good when a company has high earnings estimates, better when they continue to rise. That’s what the Rising Estimates Screen of the Day highlights. Here are three top-rated tech companies — LinkedIn (LNKD), Palo Alto Networks (PANW) and Regeneron Pharmaceuticals (REGN) — that have seen sizable increases in their earnings estimate revisions this week. Investors Connect With LinkedIn Professional networking site LinkedIn’s Q3 results, reported

Gilead, Regeneron Stocks Weather Drug Pricing Furor

Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry’s drug-pricing practices and fears of greater regulation. But two biotechs with top fundamentals — Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN), the focus of the Screen of the Day — have maintained strong ratings and held up in

Regeneron Q3 Beats Views, But Praluent Launch Slow

Big biotech Regeneron Pharmaceuticals (REGN) beat analysts’ Q3 estimates and raised its guidance Wednesday, but the stock slid as expense guidance went up and newly launched cholesterol drug Praluent missed expectations. Regeneron’s earnings rose 37% over the year-earlier quarter to $3.47 a share, beatings analysts’ consensus by 27 cents, according to Thomson Reuters. Revenue climbed 57% to $1.14 billion, about $80 million above consensus.